When
administered under labeled conditions, ReBalance is an FDA-approved,
safe and effective treatment for horses with equine protozoal
myeloencephalitis (EPM) caused by Sarcocystis neurona.
Proven safe and effective
Cost-efficient
Easy administration
Oral suspension
FDA-Approved
From A Name You Can Trust
The active
ingredients (sulfadiazine 250 mg/mL and pyrimethamine 12.5 mg/mL)
inhibit folic acid synthesis at two different sites, in the same
synthetic pathway. The combination is synergistic, with the drug
combination having an anti-protozoal effect.
Equine protozoal myeloencephalitis (EPM) is a nervous system disease caused by the protozoa Sarcocystis neurona.
Horses develop the disease by ingesting contaminated feedstuffs. The
definitive host is the opossum, but intermediate hosts have been
identified as the nine-banded armadillo, the striped skunk and the
raccoon.
EPM is an elusive disease as it presents highly variable clinical
signs that may range from head tilt, ear droop, blindness, seizures,
inability to chew or swallow, gait abnormalities, stumbling, muscle
atrophy, weakness, incoordination, ataxia, or depression.
Testing and development of an early, effective treatment plan
should be considered. It has been estimated that up to 55% to 65% of
horses respond favorably to treatment. However, it is further estimated
that a small percentage (no more than 10%) of treated horses do recover
completely.
Dosing
4 mL per
110 lb (50 kg) of body weight once per day.
The duration of treatment
is dependent upon clinical response, but the usual treatment regimen
ranges from 90 to 270 days.
When
administered under labeled conditions, ReBalance is an FDA-approved,
safe and effective treatment for horses with equine protozoal
myeloencephalitis (EPM) caused by Sarcocystis neurona.
Proven safe and effective
Cost-efficient
Easy administration
Oral suspension
FDA-Approved
From A Name You Can Trust
The active
ingredients (sulfadiazine 250 mg/mL and pyrimethamine 12.5 mg/mL)
inhibit folic acid synthesis at two different sites, in the same
synthetic pathway. The combination is synergistic, with the drug
combination having an anti-protozoal effect.
Equine protozoal myeloencephalitis (EPM) is a nervous system disease caused by the protozoa Sarcocystis neurona.
Horses develop the disease by ingesting contaminated feedstuffs. The
definitive host is the opossum, but intermediate hosts have been
identified as the nine-banded armadillo, the striped skunk and the
raccoon.
EPM is an elusive disease as it presents highly variable clinical
signs that may range from head tilt, ear droop, blindness, seizures,
inability to chew or swallow, gait abnormalities, stumbling, muscle
atrophy, weakness, incoordination, ataxia, or depression.
Testing and development of an early, effective treatment plan
should be considered. It has been estimated that up to 55% to 65% of
horses respond favorably to treatment. However, it is further estimated
that a small percentage (no more than 10%) of treated horses do recover
completely.
Dosing
4 mL per
110 lb (50 kg) of body weight once per day.
The duration of treatment
is dependent upon clinical response, but the usual treatment regimen
ranges from 90 to 270 days.